Join Growin Stock Community!

Eupraxia pharmaceuticals inc.EPRX.US Overview

US StockHealthcare
(No presentation for EPRX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EPRX AI Insights

EPRX Overall Performance

EPRX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EPRX Recent Performance

2.20%

Eupraxia pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

EPRX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EPRX Key Information

EPRX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EPRX Profile

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Price of EPRX

EPRX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EPRX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.10
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
7.10
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is EPRX's latest earnings report released?

    The most recent financial report for Eupraxia pharmaceuticals inc. (EPRX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EPRX's short-term business performance and financial health. For the latest updates on EPRX's earnings releases, visit this page regularly.

  • How much debt does EPRX have?

    As of the end of the reporting period, Eupraxia pharmaceuticals inc. (EPRX) had total debt of 170.6K, with a debt ratio of 0. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EPRX have?

    At the end of the period, Eupraxia pharmaceuticals inc. (EPRX) held Total Cash and Cash Equivalents of 88.96M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is EPRX's EPS continuing to grow?

    According to the past four quarterly reports, Eupraxia pharmaceuticals inc. (EPRX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EPRX?

    Eupraxia pharmaceuticals inc. (EPRX)'s Free Cash Flow (FCF) for the period is -4.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 55.37% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EPRX?

    The latest valuation data shows Eupraxia pharmaceuticals inc. (EPRX) has a Price-To-Earnings (PE) ratio of -6.66 and a Price/Earnings-To-Growth (PEG) ratio of 0.28. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.